San Diego, CA -- (SBWIRE) -- 10/03/2016 -- Certain directors of ProNAi Therapeutics Inc are under investigation over possible wrongdoing. The investigation was announced for investors in NASDAQ:DNAI shares over potential breaches of fiduciary duties by certain directors at ProNAi Therapeutics.

Investors who purchased shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain ProNAi Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Inc's President and CEO Nick Glover said, "Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine," the Company has "decided to suspend the development of PNT2258" because the results were not "robust enough to justify continued development of the drug in DLBCL."

Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.98 per share on June 10, 2016.

Those who purchased shares of ProNAi Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com